JCO precision oncology
Journal
Overview
publication venue for
-
Germline SMARCA4 Deletion as a Driver of Uterine Cancer: An Atypical Presentation.
2022
-
DICER1-Associated Anaplastic Sarcoma of the Kidney With Coexisting Activating PDGFRA D842V Mutations and Response to Targeted Kinase Inhibitors in One Patient.
2022
-
Tumor-Informed Versus Plasma-Only Liquid Biopsy Assay in a Patient With Multiple Primary Malignancies.
2022
-
Identification of a TP53 Deletion in an Undifferentiated Embryonal Sarcoma of the Liver Provides Clinically Relevant Longitudinal Detection of Circulating Tumor DNA.
2021
-
Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas.
2021
-
Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression.
2020
-
FGFR1 Rearrangement Guides Diagnosis and Treatment of a Trilineage B, T, and Myeloid Mixed Phenotype Acute Leukemia.
2020
-
Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations.
2020
-
Pathogenic Loss-of-Function Germline TERT Mutations in Patients With Solid Tumors.
2019
-
Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors.
2019
-
Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas.
2017
-
Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab..
7.
2023
-
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis..
7.
2023
-
Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome..
7.
2023
-
Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma..
7.
2023
-
Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group..
7.
2023
-
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers..
6.
2022
-
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer..
6.
2022
-
Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer..
6.
2022
-
Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance..
6.
2022
-
SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors..
6.
2022
-
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma..
6.
2022
-
Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer..
6.
2022
-
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype..
6.
2022
-
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience..
6.
2022
-
Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy..
6.
2022
-
Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor..
5.
2021
-
Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing..
5.
2021
-
TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence..
5.
2021
-
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer..
5.
2021
-
Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer..
5.
2021
-
Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant POLE/POLD1 Colon Cancer..
5.
2021
-
Differential Impact of ALK Mutations in Neuroblastoma..
5.
2021
-
Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient Population..
5.
2021
-
Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations..
5.
2021
-
Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study..
5.
2021
-
Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes..
4.
2020
-
Identification of a Microsatellite Stable, EGFR-Mutant Lung Adenocarcinoma Developing in a Patient With Lynch Syndrome..
4.
2020
-
Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs..
4.
2020
-
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer..
4.
2020
-
Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget's Disease of the Vulva..
4.
2020
-
Systematic Assessment of Tumor Purity and Its Clinical Implications..
4.
2020
-
CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib..
4.
2020
-
BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer..
4.
2020
-
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors..
4.
2020
-
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations..
4.
2020
-
P2RY8-CRLF2Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel Therapy..
4.
2020
-
Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers..
3.
2019
-
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials..
3.
2019
-
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer..
3.
2019
-
Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine..
3.
2019
-
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis..
3.
2019
-
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence..
3.
2019
-
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer..
3.
2019
-
Computed Tomography-Derived Radiomic Metrics Can Identify Responders to Immunotherapy in Ovarian Cancer..
3.
2019
-
Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution..
3.
2019
-
Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology..
3.
2019
-
Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases..
3.
2019
-
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers..
3.
2019
-
Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer..
3.
2019
-
Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer..
3.
2019
-
Harnessing Clinical Sequencing Data for Survival Stratification of Patients with Metastatic Lung Adenocarcinomas..
3.
2019
-
Targeting HER2/neu Oncogene Overexpression With Ado-Trastuzumab Emtansine in the Treatment of Metastatic Salivary Gland Neoplasms: A Single-Institution Experience..
3.
2019
-
Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma..
2018.
2018
-
Dramatic Response to Sequential BRAF Inhibition in BRAF V600E-Mutant Metastatic Lung Adenocarcinoma..
2.
2018
-
Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma..
2.
2018
-
Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions..
2.
2018
-
Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers..
2.
2018
-
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium..
2018.
2018
-
Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma..
2.
2018
-
Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer..
2018.
2018
-
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion..
2018.
2018
-
BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy..
2.
2018
-
Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability..
2018.
2018
-
Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations..
2.
2018
-
Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome..
2018.
2018
-
Specifying the True- and False-Positive Rates in Basket Trials..
1.
2017
-
DNA Methylation-Based Classifier for Accurate Molecular Diagnosis of Bone Sarcomas..
2017.
2017
-
Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data..
2017.
2017
-
Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma..
2017.
2017
-
PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma..
1.
2017
-
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models..
2017.
2017
-
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making..
2017.
2017
-
Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas..
2017.
2017
-
OncoKB: A Precision Oncology Knowledge Base..
2017.
2017
-
Reply to F. Dayyani et al.
2022
-
Race and Genetic Alterations in Prostate Cancer.
2021
-
Intermittent Treatment With MEK Inhibitors in Patients With Oncogenic RAF-Driven Tumors: A Potential Strategy to Manage Toxicity and Maintain Efficacy.
2018
-
Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care.
2022
-
Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.
2022
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)